Clinical Trial Site

Columbus, Ohio 43231

9 studies enrolling now · 24 studies all time

What they study most

ANCA-Associated Vasculitis, AQP4+ NMOSD, ATTR Amyloidosis, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Atypical Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), Atypical Hemolytic-Uremic Syndrome, Autism Spectrum Disorder

Studies at this site

• Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty — Recruiting now
• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris — Recruiting now
• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — Recruiting now
• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — Recruiting now
• A Prospective Sub-Study of the Global Hypophosphatasia Registry — Recruiting now
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — Recruiting now
• Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis — Running, not enrolling
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — Completed
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery — Stopped early
• Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder — Stopped early
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation — Completed
• A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia — Completed
• A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia — Completed
• A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease — Stopped early
• Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment — Stopped early
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed